$MEDP · Medpace Holdings, Inc.
Medpace reported Q3 FY2026 revenue of $716M (+8.5% YoY) and diluted EPS of $4.84, with net income of $137.5M. Operating margin was 23.1%, and income from operations rose to $165.5M from $141.8M in Q3 FY2025. For the nine months ended September 30, 2026, revenue reached $2.13B (+16.9% YoY) and net income totaled $382.7M.
- Q3 revenue $716M, up 8.5% YoY; nine-month revenue $2.13B, up 16.9%
- Diluted EPS $4.84 in Q3; net income $137.5M vs $111.1M prior year
- Operating margin 23.1% in Q3; income from operations $165.5M
- Repurchased 705,616 shares for $294.7M in nine months; $527M authorization remained at quarter-end
- New $1.0B buyback authorization approved October 20, 2026, replacing prior program
Extended-hours last trade $653.96, flat vs regular close and -0.01% vs price-at-filing. Market cap $18.25B; stock showing minimal reaction to the quarterly results.
Medpace delivered solid Q3 growth with 8.5% revenue increase and 23.1% operating margin, plus a fresh $1B buyback authorization signaling capital-return confidence.
CRO sector growth continues; Medpace's 8.5% Q3 revenue growth and 23.1% operating margin reflect steady demand for clinical trial services amid ongoing pharmaceutical R&D investment.
Direct service costs rose 9.9% YoY in Q3, outpacing revenue growth; reimbursed out-of-pocket expenses up 25.9% for nine months, pressuring margins if not passed through.
Get filings like this before the market reacts.
Real-time SEC filing alerts, AI summaries, and a free daily digest — plus portfolio tracking that ties filings to your positions.